Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Matthew A Spear"'
Autor:
Matthew B. Spear, Kristen Miller, Craig Press, Christopher Ruzas, Jaime LaVelle, Peter M. Mourani, Tellen D. Bennett, Aline B. Maddux
Publikováno v:
The Neurohospitalist. 13(1)
Background and Purpose Long-term outcomes after pediatric neurocritical illness are poorly characterized. This study aims to characterize the frequency and risk factors for post-discharge unplanned health resource use in a pediatric neurocritical car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1b1185359c0f86cbb68e8d4bfd21169
https://pubmed.ncbi.nlm.nih.gov/36531841
https://pubmed.ncbi.nlm.nih.gov/36531841
Autor:
Matthew A. Spear, Ahmet Dogan, Simon F. Lacey, Nikoletta Lendvai, Adam D. Cohen, Christopher E. Martin, Alfred L. Garfall, Dan T. Vogl, Alexander M. Lesokhin
Publikováno v:
Blood Advances. 3:2487-2490
Key Points Myeloma patients progressing on BCMA-targeted therapy can maintain BCMA expression and still respond to different BCMA-targeted therapy. These observations suggest this patient population could be included in ongoing BCMA-targeted therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::527e4f1ceaeb8938dde1554a5832757a
https://doi.org/10.1182/bloodadvances.2019000466
https://doi.org/10.1182/bloodadvances.2019000466
Autor:
Matthew A. Spear
Publikováno v:
BioTechniques, Vol 28, Iss 4, Pp 660-668 (2000)
Described here is a selective restriction endonuclease digestion method that eliminates the electrophoresis step that is usually used during the subcloning of new DNA sequences into typical E. coli-based plasmids. The method increases yield while dec
Externí odkaz:
https://doaj.org/article/7be8b0e3b16f450582038e492312b90e
Autor:
Susan F. Slovin, Tanya B. Dorff, Gerald Steven Falchook, Xiao X. Wei, Xin Gao, Rana R. McKay, David Yoonsuk Oh, Andreas Georg Wibmer, Matthew A. Spear, Joanne McCaigue, Devon J. Shedlock, Manjima Dhar, Julia Coronella, Christopher E. Martin, Majid Ghodussi, Ann Murphy, Eric M. Ostertag
Publikováno v:
Journal of Clinical Oncology. 40:98-98
98 Background: P-PSMA-101 is an autologous CAR-T therapy targeting PSMA, with a high percentage of stem cell memory T cells (TSCM) associated with efficacy, safety, and bone homing (particularly relevant to prostate cancer). It is manufactured using
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32c6609fcf7689bc849502f472887948
https://doi.org/10.1200/jco.2022.40.6_suppl.098
https://doi.org/10.1200/jco.2022.40.6_suppl.098
Autor:
Katherine McArthur, Abbas Abbas Ali, Tara K. Gregory, Christopher E. Martin, Bhagirathbhai Dholaria, Caitlin Costello, Ben A Derman, Rajneesh Nath, Joanne McCaigue, Majid Ghoddusi, Matthew A. Spear, Jesus G. Berdeja, David S. Siegel, Adam D. Cohen, Rajesh Belani, Eric M. Ostertag, Abhinav Deol, Krina K. Patel, Nina Shah, Mehmet Hakan Kocoglu, Hamid Namini
Publikováno v:
Blood. 138:3858-3858
P-BCMA-101 and P-BCMA-ALLO1, autologous and allogeneic BCMA targeting CAR-T cell therapies respectively, are manufactured using a novel transposon-based system called piggyBac (PB). They comprise a high percentage of desirable stem cell memory T-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d1f4a082cf10ce768c59c81a4bfe452
https://doi.org/10.1182/blood-2021-151672
https://doi.org/10.1182/blood-2021-151672
Autor:
Adam D. Cohen, Eric M. Ostertag, Nina Shah, Jesus G. Berdeja, Sreeni Yalamanchili, Tara K. Gregory, Mehrdad Abedi, Joanne McCaigue, Hamid Namini, Matthew A. Spear, Syed S Ali, Siddhartha Ganguly, Christopher E. Martin, Caitlin Costello, Mehmet Hakan Kocoglu, Majid Ghoddussi, Krina K. Patel, Devon J. Shedlock
Publikováno v:
Blood. 136:29-30
P-BCMA-101 is an autologous chimeric antigen receptor-T cell (CAR-T) therapeutic targeting BCMA and comprised of a high percentage of desirable stem cell memory T cells. P-BCMA-101 is manufactured using a novel transposon-based system called piggyBac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa8acef904f4122d9110d8e131d9823b
https://doi.org/10.1182/blood-2020-142695
https://doi.org/10.1182/blood-2020-142695
Autor:
Matthew A. Spear, Robert Z. Orlowski, Eric M. Ostertag, Adam D. Cohen, Jesus G. Berdeja, Tara K. Gregory, Syed Abbas Ali, Caitlin Costello, Michelle Lynn Resler, Devon J. Shedlock, Krina K. Patel, Nishan de Silva
Publikováno v:
Cancer Research. 78:CT130-CT130
Background: P-BCMA-101 is a novel chimeric antigen receptor (CAR)-T cell therapy designed to increase efficacy while minimizing toxicity through reduced immunogenicity, lack of tonic signaling, a safety switch, high purity (>95% CAR+) and a Tscm ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4f2ddf387202ed28d1a9107deef2620
https://doi.org/10.1158/1538-7445.am2018-ct130
https://doi.org/10.1158/1538-7445.am2018-ct130
Autor:
Krina K. Patel, Caitlin Costello, Matthew A. Spear, Devon J. Shedlock, Adam D. Cohen, Tara K. Gregory, Syed Abbas Ali, Jesus G. Berdeja, Majid Ghoddusi, Christopher E. Martin, Eric M. Ostertag, Robert Z. Orlowski, Nina Shah
Publikováno v:
Blood. 134:3184-3184
P-BCMA-101 is a novel chimeric antigen receptor (CAR)-T cell product targeting B Cell Maturation Antigen (BCMA). P-BCMA-101 is produced using the piggyBac® (PB) DNA Modification System instead of the viral vector that is used with most CAR-T cells,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2afaf768ff73153823fe9df62f44f7fe
https://doi.org/10.1182/blood-2019-129562
https://doi.org/10.1182/blood-2019-129562
Autor:
Saskia T. C. Neuteboom, Shawgi Sukumaran, Matthew A. Spear, G. Kenneth Lloyd, Timothy J. Price, Girish Sharma, Ana Lay, David J. McConkey, Michael A. Palladino, Christopher Sweeney, Angie M. Longenecker, Harry A. Drabkin, Amanda R. Townsend, Robert M. Gemmill, Andrew Spencer, Michael Millward, Lonnie Lee
Publikováno v:
Investigational New Drugs. 30:2303-2317
Purpose Combining proteasome and histone deacetylase (HDAC) inhibition has been seen to provide synergistic anti-tumor activity, with complementary effects on a number of signaling pathways. The novel bi-cyclic structure of marizomib with its unique
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45b0c93e8badd861ec3ae08f800100fc
https://doi.org/10.1007/s10637-011-9766-6
https://doi.org/10.1007/s10637-011-9766-6
Autor:
Irene M. Ghobrial, KC Anderson, Saskia T. C. Neuteboom, E. Valashi, G. K. Lloyd, William H. McBride, Paul G. Richardson, Barbara C. M. Potts, Joya Chandra, Huib Ovaa, Michael A. Palladino, Callum M. Sloss, Michael Groll, William Fenical, Aldo M. Roccaro, Frank Pajonk, Anas Younes, Y. Oki, James C. Cusack, Paul R. Jensen, Celia R. Berkers, Claudia P. Miller, M. X. Albitar, Stavroula Baritaki, Kin S. Lam, David J. McConkey, Ben Bonavida, D Chauhan, Matthew A. Spear
Publikováno v:
Current Cancer Drug Targets. 11:254-284
The proteasome has emerged as an important clinically relevant target for the treatment of hematologic malignancies. Since the Food and Drug Administration approved the first-in-class proteasome inhibitor bortezomib (Velcade®) for the treatment of r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab2ae9e187e8864778eee530baefda2b
https://doi.org/10.2174/156800911794519716
https://doi.org/10.2174/156800911794519716